EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy

Lakshini Y Herat, Jennifer R Matthews, Elizabeth P Rakoczy, Markus P Schlaich, Vance B Matthews

Frontiers in Bioscience-Landmark · 2023

DOI: 10.31083/j.fbl2804083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Lakshini Y Herat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dobney Hypertension Centre, School of Biomedical Sciences - Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Retinal Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Perth Hospital-Research Foundation WA, Diabetes Australia Research Program, Diabetes Research WA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic retinopathy (DR) is a leading cause of end-stage blindness globally and is arguably one of the most disabling complications of both Type 1 and Type 2 diabetes. Sodium Glucose Cotransporter-2 (SGLT2) inhibitors have now been successfully introduced to clinical medicine and exert multiple beneficial effects in diabetic patients. Given the broad therapeutic application of SGLT2 inhibitors, we hypothesised that SGLT2 inhibition may alleviate the progression of DR. Therefore, we aimed to compare the effectiveness of two clinically available SGLT2 inhibitors, Empagliflozin and Canagliflozin, on the progression of Retinopathy and DR using well-characterised mouse models, Kimba and Akimba, respectively.

Methods

Empagliflozin, Canagliflozin (25 mg/kg/day) or vehicle was administered to 10-week-old mice via drinking water for 8-weeks. Urine glucose levels were measured to ascertain SGLT2 inhibition promoted glucose excretion. Weekly body weight and water intake measurements were obtained. After 8-weeks of treatment, body weight, daily water intake, fasting blood glucose levels were measured and eye tissue was harvested. The retinal vasculature was assessed using immunofluorescence.

Results

Empagliflozin treated Akimba mice exhibited metabolic benefits suggested by healthy body weight gain and significantly reduced fasting blood glucose levels. Treatment with Empagliflozin reduced retinal vascular lesions in both Kimba and Akimba mice. Canagliflozin improved body weight gain, reduced blood glucose levels in Akimba mice, and reduced the development of retinal vascular lesions in Kimba mice.

Conclusions

Our data demonstrates that Empagliflozin has future potential as a therapeutic for Retinopathy and DR and should now be considered for human trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Retinal DiseasesHumansMiceAnimalsCanagliflozinSodium-Glucose Transporter 2Blood GlucoseHypoglycemic AgentsGlucoseBody WeightBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

AkimbaKimbaSGLT2 inhibitorscanagliflozindiabetesdiabetic retinopathyempagliflozinmouse modelsretinal vasculaturesodium glucose cotransporters

Substanzen

CanagliflozinSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2Blood GlucoseHypoglycemic AgentsGlucoseempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Dobney Hypertension Centre, School of Biomedical Sciences - Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia.
  • Department of Molecular Ophthalmology, University of Western Australia, Crawley, WA 6009, Australia.
  • Dobney Hypertension Centre, Medical School - Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia.
  • Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA 6000, Australia.

Förderung

  • Royal Perth Hospital-Research Foundation WA
  • Diabetes Australia Research Program
  • Diabetes Research WA
  • Raine Medical Research Foundation, WA

Zitieren

APA

Herat, L. Y., Matthews, J. R., Rakoczy, E. P., Schlaich, M. P., & Matthews, V. B. (2023). Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2804083

Vancouver

Herat LY, Matthews JR, Rakoczy EP, Schlaich MP, Matthews VB. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2804083

BibTeX
@article{Herat2023,
  author = {Herat, Lakshini Y and Matthews, Jennifer R and Rakoczy, Elizabeth P and Schlaich, Markus P and Matthews, Vance B},
  title = {Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  doi = {10.31083/j.fbl2804083}
}
Kostenlos starten →